Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice) - PubMed (original) (raw)
. 2002 Aug 15;100(4):1123-32.
doi: 10.1182/blood-2002-06-1913.
Affiliations
- PMID: 12149188
- DOI: 10.1182/blood-2002-06-1913
Free article
Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice)
Alessandro Maria Vannucchi et al. Blood. 2002.
Free article
Abstract
The phenotype induced by the GATA-1(low) (neodeltaHS) mutation is here further characterized by analyzing the hemopoietic system during the aging (up to 20 months) of a GATA-1(low) colony (135 mutants and 40 normal littermates). Mutants expressed normal hematocrit values (Hct = 45.9 +/- 4.0) until 12 months but became anemic from 15 months on (Hct = 30.9 +/- 3.9; P <.05). Anemia was associated with several markers of myelofibrosis such as the presence of tear-drop poikilocytes and progenitor cells in the blood, collagen fibers in the marrow and in the spleen, and hemopoietic foci in the liver. Semiquantitative reverse transcription-polymerase chain reaction showed that growth factor genes implicated in the development of myelofibrosis (such as osteocalcin, transforming growth factor-beta1, platelet-derived growth factor, and vascular endothelial growth factor) were all expressed in the marrow from the mutants at higher levels than in corresponding normal tissues. The GATA-1(low) mutants experienced a slow progression of the disease because the final exitus was not observed until at least 15 months with a probability of survival more favorable than that of W/Wv mice concurrently kept in the animal facility (P <.001, by Kaplan-Meier analysis). In conclusion, impaired GATA-1 expression may contribute to the development of myelofibrosis, and the GATA-1(low) mutants may represent a suitable animal model for the human disease that may shed light on its pathogenesis.
Comment in
- An animal model for myelofibrosis.
Shivdasani R. Shivdasani R. Blood. 2002 Aug 15;100(4):1109. doi: 10.1182/blood-2002-06-1856. Blood. 2002. PMID: 12149182 No abstract available. - Lack of alteration in GATA-1 expression in CD34+ hematopoietic progenitors from patients with idiopathic myelofibrosis.
Martyré MC, Steunou V, LeBousse-Kerdilès MC, Wietzerbin J. Martyré MC, et al. Blood. 2003 Jun 15;101(12):5087-8; author reply 5088-9. doi: 10.1182/blood-2002-11-3366. Blood. 2003. PMID: 12788793 No abstract available.
Similar articles
- A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.
Vannucchi AM, Bianchi L, Paoletti F, Pancrazzi A, Torre E, Nishikawa M, Zingariello M, Di Baldassarre A, Rana RA, Lorenzini R, Alfani E, Migliaccio G, Migliaccio AR. Vannucchi AM, et al. Blood. 2005 May 1;105(9):3493-501. doi: 10.1182/blood-2004-04-1320. Epub 2005 Jan 21. Blood. 2005. PMID: 15665119 - Accentuated response to phenylhydrazine and erythropoietin in mice genetically impaired for their GATA-1 expression (GATA-1(low) mice).
Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Carrai V, Calzolari A, Centurione L, Lorenzini R, Carta C, Alfani E, Sanchez M, Migliaccio G, Migliaccio AR. Vannucchi AM, et al. Blood. 2001 May 15;97(10):3040-50. doi: 10.1182/blood.v97.10.3040. Blood. 2001. PMID: 11342429 - Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice.
Centurione L, Di Baldassarre A, Zingariello M, Bosco D, Gatta V, Rana RA, Langella V, Di Virgilio A, Vannucchi AM, Migliaccio AR. Centurione L, et al. Blood. 2004 Dec 1;104(12):3573-80. doi: 10.1182/blood-2004-01-0193. Epub 2004 Aug 3. Blood. 2004. PMID: 15292068 - Impaired GATA-1 expression and myelofibrosis in an animal model.
Vannucchi AM, Bianchi L, Paoletti F, Di Giacomo V, Migliaccio G, Migliaccio AR. Vannucchi AM, et al. Pathol Biol (Paris). 2004 Jun;52(5):275-9. doi: 10.1016/j.patbio.2004.02.008. Pathol Biol (Paris). 2004. PMID: 15217713 Review. - GATA transcription factors in hematologic disease.
Cantor AB. Cantor AB. Int J Hematol. 2005 Jun;81(5):378-84. doi: 10.1532/ijh97.04180. Int J Hematol. 2005. PMID: 16158817 Review.
Cited by
- To condition or not to condition-That is the question: The evolution of nonmyeloablative conditions for transplantation.
Migliaccio AR. Migliaccio AR. Exp Hematol. 2016 Aug;44(8):706-12. doi: 10.1016/j.exphem.2016.04.016. Epub 2016 May 6. Exp Hematol. 2016. PMID: 27157594 Free PMC article. Review. - GATA1 Activity Governed by Configurations of _cis_-Acting Elements.
Hasegawa A, Shimizu R. Hasegawa A, et al. Front Oncol. 2017 Jan 9;6:269. doi: 10.3389/fonc.2016.00269. eCollection 2016. Front Oncol. 2017. PMID: 28119852 Free PMC article. Review. - STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice.
Huang Z, Richmond TD, Muntean AG, Barber DL, Weiss MJ, Crispino JD. Huang Z, et al. J Clin Invest. 2007 Dec;117(12):3890-9. doi: 10.1172/JCI33010. J Clin Invest. 2007. PMID: 18060035 Free PMC article. - Immature and mature megakaryocytes enhance osteoblast proliferation and inhibit osteoclast formation.
Ciovacco WA, Cheng YH, Horowitz MC, Kacena MA. Ciovacco WA, et al. J Cell Biochem. 2010 Mar 1;109(4):774-81. doi: 10.1002/jcb.22456. J Cell Biochem. 2010. PMID: 20052670 Free PMC article. - Evidence for organ-specific stem cell microenvironments.
Ghinassi B, Martelli F, Verrucci M, D'Amore E, Migliaccio G, Vannucchi AM, Hoffman R, Migliaccio AR. Ghinassi B, et al. J Cell Physiol. 2010 May;223(2):460-70. doi: 10.1002/jcp.22055. J Cell Physiol. 2010. PMID: 20112287 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases